Tissue Regenix Group, a regenerative medical devices company, has appointed Gareth Hywel Jones as Chief Financial Officer. He will join the Group as CFO, company secretary and as an executive director on the board on 30 November 2018.
Jones, who will join the Group from Applied Graphene Materials plc (AGM), is an experienced CFO, bringing significant operational, high technology manufacturing and strategic financial expertise gained through roles in UK and US listed businesses as well as private equity.
Current interim CFO, Paul Below, will remain with the group to facilitate an orderly hand-over.
Steve Couldwell, CEO Tissue Regenix Group, commented: “We are delighted to announce the appointment of Gareth as our Chief Financial Officer. After an extensive recruitment process, Gareth’s proven experience of implementing operational enhancements, divisional business unit management, profit improvement initiatives and strategic commercial planning, in both UK and US quoted companies, will significantly strengthen our leadership team. I look forward to welcoming Gareth to the Group in November.”
Gareth Jones, CFO – Designate for Tissue Regenix, commented: “Tissue Regenix is at an exciting inflection point in terms of executing against its commercial growth strategy."
"With tangible and growing traction in the US markets and multiple EU product launches expected, I look forward to working with the executive team and board as the company continues to deliver strong organic growth from its innovative products.”